Standard BioTools Inc. $LAB is Casdin Capital LLC’s 4th Largest Position

Casdin Capital LLC raised its position in shares of Standard BioTools Inc. (NASDAQ:LAB) by 1.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 77,558,856 shares of the company’s stock after acquiring an additional 1,483,220 shares during the quarter. Standard BioTools makes up approximately 8.4% of Casdin Capital LLC’s holdings, making the stock its 4th largest position. Casdin Capital LLC owned 0.20% of Standard BioTools worth $100,827,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LAB. Russell Investments Group Ltd. raised its position in shares of Standard BioTools by 2,989.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock worth $33,000 after acquiring an additional 24,211 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Standard BioTools by 50.3% during the second quarter. BNP Paribas Financial Markets now owns 29,826 shares of the company’s stock valued at $36,000 after purchasing an additional 9,986 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of Standard BioTools by 103.6% during the third quarter. Federated Hermes Inc. now owns 28,545 shares of the company’s stock valued at $37,000 after purchasing an additional 14,523 shares in the last quarter. SG Americas Securities LLC grew its stake in Standard BioTools by 167.8% in the third quarter. SG Americas Securities LLC now owns 33,039 shares of the company’s stock worth $43,000 after purchasing an additional 20,700 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Standard BioTools in the second quarter worth $43,000. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Standard BioTools Stock Up 0.2%

Standard BioTools stock opened at $0.93 on Friday. The company has a market capitalization of $358.65 million, a P/E ratio of -4.66 and a beta of 1.36. The stock’s 50 day moving average is $1.28 and its 200 day moving average is $1.32. Standard BioTools Inc. has a twelve month low of $0.92 and a twelve month high of $1.72.

Standard BioTools (NASDAQ:LAB) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.08. The company had revenue of $23.80 million during the quarter, compared to analyst estimates of $18.50 million. Standard BioTools had a negative return on equity of 11.20% and a negative net margin of 59.39%. As a group, equities analysts expect that Standard BioTools Inc. will post -0.29 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the company. Zacks Research raised Standard BioTools to a “hold” rating in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Standard BioTools in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Standard BioTools from a “hold” rating to a “sell” rating in a research note on Sunday, March 8th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Standard BioTools currently has a consensus rating of “Reduce” and an average target price of $1.35.

Standard BioTools Profile

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.